Phase I study to assess the histologic effect and safety of pre-operative and post-operative infusions of IL13-PE38QQR [cintredekin besudotox] cytotoxin in patients with recurrent resectable supratentorial malignant glioma.

Trial Profile

Phase I study to assess the histologic effect and safety of pre-operative and post-operative infusions of IL13-PE38QQR [cintredekin besudotox] cytotoxin in patients with recurrent resectable supratentorial malignant glioma.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 May 2014

At a glance

  • Drugs Cintredekin besudotox (Primary)
  • Indications Anaplastic astrocytoma; Astrocytoma; Glioblastoma; Glioma
  • Focus Adverse reactions
  • Sponsors INSYS Therapeutics, Inc
  • Most Recent Events

    • 03 Jun 2011 Actual end date (Jul 2007) added as reported by ClinicalTrials.gov.
    • 03 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Apr 2011 Company added (INSYS Therapeutics) as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top